15-17-1 ⓔ文献
Osteoporosis prevention, diagnosis, and therapy. NIH Consens Statement, 2000; 17: 1–45.
骨粗鬆症の予防と治療ガイドライン作成委員会：骨粗鬆症の予防と治療ガイドライン 2015年版，日本骨粗鬆症学会・日本骨代謝学会・骨粗鬆症財団，2015.
Orimo H, Yaegashi Y, et al: Hip fracture incidence in Japan: estimates of new patients in 2012 and 25–year trends. Osteoporos Int, 2016; 27: 1777–1784.
Khosla S, Atkinson EJ, et al: Effects of age and estrogen status on serum parathyroid hormone levels and biochemical markers of bone turnover in women: a population–based study. J Clin Endocrinol Metab, 1997; 82: 1522–1527.
Bilzkian JP: Primary hyperparathyroidism. J Clin Endocrinol Metab, 2018; 103: 3993–4004.
Almeida M, Laurent MR, et al: Estrogens and androgens in skeletal physiology and pathophysiology. Physiol Rev, 2017; 97: 135–187.
Futo L, Toke J, et al: Skeletal differences in bone mineral area and content before and after cure of endogenous Cushing’s syndrome. Osteoporos Int, 2008; 19: 941–949.
Schorr M, Klibanski A: Anorexia nervosa and bone. Curr Opin Endocr Metab Res, 2018; 3: 74–82.
Suzuki Y, Nawata H, et al: Guidelines on the management and treatment of glucocorticoid–induced osteoporosis of the Japanese Society for Bone and Mineral Research 2014 update. J Bone Miner Metab, 2014; 32: 337–350.
Zhu AN, Jiang YF, et al: Risk of fracture with thiazolidinediones: an updated meta–analysis of randomized clinical trials. Bone, 2014; 68: 115–123.
Bikle DD, Sakata T, et al: The impact of skeletal unloading on bone formation. Gravit Space Biol Bull, 2003; 16: 45–54.
Marini JC, Forlino A, et al: Osteogenesis imperfecta. Nat Rev Dis Primers, 2017; 3: 17052.
Kohlmeier L, Gasner C, et al: The bone mineral status of patients with Marfan syndrome. J Bone Miner Res, 1995; 10: 1550–1555.
日本骨粗鬆症学会生活習慣病における骨折リスク編集委員会編：生活習慣病骨折リスクに関する診療ガイド 2019年版，日本骨粗鬆症学会，2019.
Genant HK, Wu CY, et al: Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res, 1993; 8: 1137–1148.
Leib ES, Lewiecki EM, et al: Official positions of the international society for clinical densitometry. J Clin Densitom, 2004; 7: 1–5.
日本骨代謝学会，日本骨粗鬆症学会合同骨粗鬆症診断基準改定検討委員会：原発性骨粗鬆症の診断基準2012年度改訂版．Osteoporos Jpn, 2013; 21: 9–21.
日本骨粗鬆症学会 骨代謝マーカー編集委員会編：骨粗鬆症診療における骨代謝マーカーの適正使用ガイド 2018年版，日本骨粗鬆症学会，2018.
Shiraki M, Kuroda T, et al: Established osteoporosis associated with high mortality after adjustment for age and co–mobidities in postmenopausal Japanese women. Intern Med, 2011; 50: 397–404.
厚生労働省：平成30年度国民健康・栄養調査の結果の概要．https://www.mhlw.go.jp/content/10900000/000584138.pdf
Hossein–nezhad A, Holick MF: Vitamin D for health: a global perspective. Mayo Clin Proc, 2013; 88: 720–755.
サルコペニア診療ガイドライン作成委員会編：サルコペニア診療ガイドライン 2017年版，ライフサイエンス出版，2017.
Adler RA, El–Hajj Fuleihan G, et al: Managing osteoporosis patients after long–term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res, 2016; 31: 16–35.
Lacey DL, Boyle WJ, et al: Bench to bedside: elucidation of the OPG-RANK–RANKL pathway and the development of denosumab. Nat Rev Drug Discov, 2012; 11: 401–419.
Hadji P: The evolution of selective estrogen receptor modulators in osteoporosis therapy. Climacteric, 2012; 15: 513–523.
Leder BZ: Parathyroid hormone and parathyroid hormone–related protein analogs in osteoporosis therapy. Curr Osteoporos Rep, 2017; 15: 110–119.
Cosman F, Crittenden DB, et al: Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med, 2016; 375: 1532–1543.
Matsumoto T, Takano T, et al: Vitamin D analogs and bone: preclinical and clinical studies with eldecalcitol. Bonekey Rep, 2014; 3: 513.
Mott A, Bradley T, et al: Effect of vitamin K on bone mineral density and fractures in adults: an updated systematic review and meta–analysis of randomised controlled trials. Osteoporos Int, 2019; 30: 1543–1559.
Knopp JA, Diner BM, et al: Calcitonin for treating acute pain of osteoporotic vertebral compression fractures: a systematic review of randomized, controlled trials. Osteoporos Int, 2005; 16: 1281–1290.